Herbalife Nutrition Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLF research report →
Range $21 – $21
Price Chart
About the company
Herbalife Nutrition Ltd. is a global enterprise dedicated to providing comprehensive nutritional solutions. Its market presence extends across various international regions, including North America, Mexico, Central and South America, Europe, the Middle East, Africa, China, and the broader Asia Pacific area.
- CEO
- John G. DeSimone
- IPO
- 2004
- Employees
- 8,500
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on HLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.63B
- P/E
- 8.95
- Fwd P/E
- 6.40
- PEG
- -0.20
- P/S
- 0.31
- P/B
- -4.00
- EV/EBITDA
- 6.20
- Div Yield
- 0.00%
- Gross Margin
- 76.46%
- Op Margin
- 9.06%
- Net Margin
- 3.37%
- ROE
- -38.70%
- ROIC
- 18.16%
Latest fiscal year · YoY change
- Revenue
- $5.04B+0.9%
- Gross Profit
- $3.81B-2.1%
- Op Income
- $441.50M
- Net Income
- $228.30M-10.2%
- EPS
- $2.22-12.3%
- OCF Growth
- +16.8%
- FCF Growth
- +54.8%
- 52W High
- $20.40
- 52W Low
- $9.78
- 50D MA
- $13.56
- 200D MA
- $13.89
- Beta
- 0.75
- RSI (14)
- 60
- Avg Volume
- 1.58M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Herbalife posted a stronger-than-guided third quarter with 6% reported sales growth, margin improvement, and raised full-year sales outlook, while leaning into nutrition clubs, a new flexible tech platform, and Bioniq as growth drivers.· November 2, 2026
- Q3 net sales were $1.4 billion, up 6% reported and 7.6% constant currency, marking the fifth straight quarter of year-over-year sales growth.
- Adjusted EBITDA was $182 million and adjusted EBITDA margin improved 70 basis points to 13.5%, both above guidance.
- Gross profit margin was 77.3%, down 40 basis points year over year, but pricing and FX helped offset mix and cost pressures.
- Management raised full-year net sales guidance and kept full-year adjusted EBITDA guidance intact on a reported basis while lifting the constant-currency EBITDA range.
- Leadership highlighted nutrition clubs, a modular technology platform, and Bioniq as key strategic priorities; the company also plans to start share repurchases in Q4.
Third quarter net sales were $1.4 billion, up 6% year over year on a reported basis and up 7.6% in constant currency, exceeding guidance. Adjusted EBITDA was $182 million versus guidance of $160 million to $180 million, and adjusted EBITDA margin was 13.5%, up 70 basis points year over year. Gross profit margin was 77.3%, down 40 basis points year over year. Diluted EPS was $0.55, up $0.13 year over year; adjusted diluted EPS was $0.64, up $0.14. Net income attributable to Herbalife was $59 million, up 36% year over year. Year-to-date operating cash flow was $298 million, up $63 million, and the company finished the quarter with $409 million of cash. For Q4, management expects reported net sales to increase 0.5% to 4.5% year over year, with a 200 basis point currency headwind, and constant-currency net sales to increase 2.5% to 6.5%. Q4 adjusted EBITDA is expected to be $145 million to $165 million reported and $155 million to $175 million constant currency. For full year 2026, reported net sales guidance was raised to 4.9% to 5.9% growth and constant-currency net sales to 5.3% to 6.3% growth. Full-year adjusted EBITDA guidance remains $670 million to $690 million reported, while the constant-currency range was raised to $700 million to $720 million. 2026 CapEx is expected to be $55 million to $65 million, with capitalized and prepaid SaaS implementation costs of $35 million to $45 million.
John DeSimone struck an optimistic, execution-focused tone, saying Herbalife has meaningful growth opportunities by strengthening the core business and better supporting distributors. He emphasized that the company’s model is built around entrepreneurial distributors and said the strategy is to provide tailored products, training, programs, and digital tools for the different ways they operate. He highlighted three priorities: a dedicated nutrition club organization, a more modular technology platform, and expansion through Bioniq. He also framed GLP-1 users, nutrition clubs, and community-based fitness events like the 24 games as growth opportunities rather than threats.
Scott Schaefer focused on the quarter’s beat versus guidance, margin math, cash generation, and capital deployment. He said FX was a 160 basis point headwind to net sales, gross margin was 77.3% and down 40 basis points year over year, and adjusted EBITDA margin was 13.5%, up 70 basis points. He noted operating cash flow of more than $151 million in the quarter and $298 million year to date, with $409 million of cash on hand, $88 million of debt paydown, and only $50 million drawn on the revolver. He also said net leverage improved to 2.0x from 2.2x, the company plans to begin repurchasing shares under its $250 million authorization in Q4, and margin expansion should be more gradual going forward.
The main analyst question focused on whether Herbalife is adjusting its product offering around GLP-1 users and on how to prioritize Pro2col, Bioniq, and Life I/O. DeSimone said the current product set can already serve GLP-1 consumers and that the opportunity is more about positioning and packaging than creating new products. On Bioniq, he said the brand has more energy than current sales and will be expanded into a fuller premium wellness portfolio, while Life I/O will be folded into Bioniq. On Pro2col, he said it was only meant to be one element of the customer engagement platform, usage is low, and the company is shifting to a broader modular platform starting with the 24 games in Q1 2027 and then other distributor business models.
The quarter showed sales and EBITDA ahead of guidance, with the company extending its run of growth to five straight quarters of reported sales increases and 10 of the last 12 quarters of constant-currency growth. Management sounded confident that nutrition clubs, a flexible digital ecosystem, and Bioniq can open new avenues of growth without requiring a full reinvention of the business. Strong cash flow, lower leverage, and the planned share repurchase program add to the positive setup.
Gross margin declined year over year, and management said the path to further adjusted EBITDA margin expansion will be more gradual, with Q4 margin expected to be lower than Q3. FX remains a meaningful headwind, and India’s strong growth may be lapping easier comparisons related to GST, which management flagged as it moves into Q4. The new tech platform is still early, Pro2col usage is low, and management is still building the broader ecosystem that is supposed to drive future engagement and transactions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.2%
- Shares Outstanding
- 104.90M
- Float Shares
- 101.91M
of shares held by institutions
257 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HLF, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Michael T. McCaulHouse · TX10 | Sell | May 6, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 6, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Feb 15, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 4, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 14, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 11.71M | ▼ 460.96K |
| Baupost Group LLC/Ma | 10.26M | ▲ 1.00M |
| Blackrock, Inc. | 8.41M | ▲ 39.92K |
| Route One Investment Company, L.P. | 8.35M | ▲ 121.50K |
| Vanguard Portfolio Management LLC | 6.07M | ▼ 123.28K |
| Renaissance Technologies LLC | 4.57M | ▼ 450.70K |
| Vanguard Capital Management LLC | 4.41M | ▼ 6.40K |
| Geode Capital Management, LLC | 3.59M | ▲ 126.46K |
| Arrowstreet Capital, Limited Partnership | 3.19M | ▲ 922.48K |
| Solel Partners LP | 2.85M | ▲ 987.50K |
| State Street Corp | 2.55M | ▲ 6.82K |
| Lsv Asset Management | 2.55M | ▼ 72.52K |
Held by 262 ETFs
Biggest fund positions in HLF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | DeSimone John | other | 34,593 |
| Nov 4, 26 | Schaefer Scott Stephen | other | 3,391 |
| Nov 1, 26 | Schaefer Scott Stephen | other | 0 |
| Nov 1, 26 | Schaefer Scott Stephen | other | 0 |
| Aug 4, 26 | Lamberti Frank | other | 1,710 |
| Jun 4, 26 | L'Helias Sophie | buy | 1,200 |
| May 18, 26 | Hicks Troy | other | 65,789 |
| May 18, 26 | Hicks Troy | other | 17,481 |
| May 18, 26 | Hicks Troy | other | 65,789 |
| May 18, 26 | Hicks Troy | other | 17,481 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HLF coverage
Recent articles, reports, and earnings notes.
No research on HLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLF report →Herbalife CFO to Participate in Fireside Chat at Bank of America Leveraged Finance Conference on December 1
businesswire.com · Nov 20
Herbalife Launches Fuel Her Power, a Nutrition Guide for Active Women
businesswire.com · Nov 19
Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19
businesswire.com · Nov 6
Why Herbalife Stock Is Up Today
fool.com · Nov 3
What Herbalife (HLF) Said on Its Q3 Earnings Call
marketbeat.com · Nov 2
Herbalife Ltd. (HLF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Herbalife Ltd (HLF) Misses Q3 Earnings Estimates
zacks.com · Nov 2
Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion
businesswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.